Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2025)

Revolution Medicines (RVMD) has 3 years of Amortization of Deferred Charges data on record, last reported at $11.9 million in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges changed N/A year-over-year to $11.9 million; the TTM value through Dec 2025 reached $23.4 million, up 1299.1%, while the annual FY2025 figure was $24.2 million, N/A changed from the prior year.
  • Amortization of Deferred Charges reached $11.9 million in Q4 2025 per RVMD's latest filing, up from $11.4 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $11.9 million in Q4 2025 and bottomed at $691000.0 in Q3 2021.